Akademik Unvanlar :

Yardımcı Doçentlik Tarihi : 25.04.2011       

Doçentlik Tarihi : 27.01.2014

Yurtdışı Gözlemci Olarak Eğitim Dönemi :

1.    Cleveland Clinic Department of Molecular and Functional Imaging Observership Program Cleveland/USA - 2005

2.    Unıversity of Pittsburgh Department of Nuclear Medicine PET/CT Observership Program Pittsburgh/USA - 2007

Başarı Belgeleri :

1.    Üniversitelerarası Kurul Yabancı Dil Sınavı (ÜDS) - İngilizce Sağlık Bilimleri - 86.250 – 25.03.2007

2.    Turkish Board of Nuclear Medicine - Kasım 2009

3.    European Board of Nuclear Medicine - Mayıs 2010

Yayınlar :

1. Uluslararası hakemli dergilerde yayınlanan makaleler :

A1. Cokmert S, Tanriverdi O, Karapolat I, Demir L, Bayoglu V, Can A, Akyol M, Yılmaz Y, Oktay Tarhan M. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study. JBUON. 2016 Nov-Dec;21(6):1410-1418.

A2. Öztürk H, Karapolat I. 18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer. Oncol Lett. 2016 Jan;11(1):316-322. 

A3. Karapolat I, Karapolat HU, Kirazli Y, Capaci K, Akkoc Y, Kumanlioglu K. Longitudinal study of bone loss in chronic spinal cord injury patients. J Phys Ther Sci. 2015 May;27(5):1429-33.

A4. Ozturk H, Karapolat I, Saklamaz A. Bilateral metachronous adrenal metastases of operated renal cell carcinoma. Urologia. 2015 Apr-Jun;82(2):114-7.

A5. Öztürk H, Karapolat I. Efficacy of 18F-fluorodeoxyglucose-positron emission  tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy. Exp Ther Med. 2015 Mar;9(3):717-724.

A6. Oncel G, Oncel D, Karapolat I, Sever F. The effectiveness of whole body magnetic resonance imaging (diffusion-weighted imaging and fat saturated T2-weighted imaging) in the evaluation of patients with newly diagnosed malignancies in comparison with positron emission tomography-computed tomography. JBR-BTR. 2014 Nov-Dec;97(6):341-5.

A7. Karapolat I, Sertpoyraz F, Oncel G, Kobak S, Yalcin M, Kumanlioglu K. Demonstrating disease activity in patients with rheumatoid arthritis. Is 18F FDG PET a sensitive method? Nuklearmedizin. 2013 Dec 13;52(6):244-9.

A8. Karapolat I, Kalfa M, Keser G, Yalcin M, Inal V, Kumanlioglu K, Parildar T, Aksu K. Comparison of F18 FDG PET/CT findings with current clinical disease status in patients with Takayasu's arteritis. Clin Exp Rheumatol. 2013, 31, 1, Suppl.75:0015-0021.

A9. Sanal SM, Sivrikoz ON, Karapolat I, Karademir S. Complete clinical response in squamous cell carcinoma of the rectum with liver metastases. J Clin Oncol. 2011 Nov 20;29(33):e806-8.

A10. Turker O, Karapolat I, Doğan I. A semihot-semicold but pure adenoma. Thyroid 2008;18:793.

A11. Turker O, Karapolat I. There is immunological benefit of selenium treatment in autoimmune thyroiditidis. Thyroid 2008;18:671-2.

A12. Yulug B, Bakar M, Karapolat I, Guzel O, Schäbitz WR. A case of idiopathic basal ganglia calcification presenting with only acting-out attacks and mild cognitive impairment: PET findings. J. Neuropsychiatry Clin. Neurosci. 2007;19:348-9.

A13. Yulug B, Bakar M, Karapolat I, Guzel O, Schäbitz WR. Topiramate improves glucose  metabolism in choreatic and depressive patient: PET findings. J. Neuropsychiatry Clin. Neurosci. 2007;19:346-7.

A14. Akgun A, Cok G, Karapolat I, Goksel T, Burak Z. Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer. Ann. Nucl. Med. 2006;20:269-75.

A15. Turker O, Kumanlioglu K, Karapolat I, Dogan I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J. Endocrinol. 2006;190:151-6.

      B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan  bildiriler :

B1. Fidan Yildiz, Inanc Karapolat, Güray Oncel. Role of quantitative perfusion scintigraphy evaluation in determination of the efficiency of the procedure before lung volume reduction coil (LVRC) treatment for severe emphysema. European Respiratory Society International Congress, London, UK, 2016

B2. Karapolat Inanc, Sertpoyraz Filiz, Oncel Guray, Kobak Senol, Kumanlioglu Kamil. Is F-18 FDG PET a sensitive method in demonstrating disease activity in patients with rheumathoid arthritis? Second Balkan Congress of Nuclear Medicine Belgrade, Serbia, 2013.

B3. Yilmaz, E; Akkoclu, A; Gulsen, A; Sever, F; Genc, B; Kalaycioglu, S; Karapolat, I; Onen, A. Comparison of diffusion-weighted magnetic resonance imaging versus F-18 fluorodeoxyglucose positron emission tomography in the assessment of N2 lymph node metastasis due to non-small cell lung cancer. World Conference on Lung Cancer (WCLC), Sydney, Australia, 2013.

B4. Argon, M; Tani, E; Omur, O; Oral, A; Karapolat, I; Yararbas, U. The value of diffuse slow washout rate of Tl-201 in type 2 diabetes mellitus patients with and without perfusion defects in myocardial perfusion scintigraphy. 25th Annual Congress of the European Association of Nuclear Medicine (EANM), Milan, Italy, 2012.

B5. Akgun A, Yuceyar N, Karapolat I, Ozbelen Alper Y, Kocaman A. Is There any Correlation Between Fatigue in Multipl Sclerosis and Cerebral Blood Flow as Detected by Tc-99m HMPAO SPECT?. Annual Congress of the EANM, Istanbul, Turkey 2005.

B6. Akgun A, Cok G, Karapolat I, Goksel T, Burak Z. Tc-99m MIBI SPECT as an indicator of prognosis for patients with small cell lung cancer. Annual Congress of the EANM, Istanbul, Turkey 2005.

B7. Hacibeyoglu I, Ozyurt O, Asıkoglu M, Karapolat I, Tunc M. Biodistribution of F-18 FDG (fluoro-2-deoxyglucose) in rabbits. International Congress of Radiopharmacy and Radiopharmaceutical Chemistry, Istanbul, Turkey 2004. 

B8. Özcan Z, Karapolat I, Dirlik A, Ömür Ö, Kumanlıoğlu K, Özkılıç H. Papillary Thyroid Carcinoma in Childhood and Adolescence. Annual Congress of the EANM, Amsterdam, Holland, 2003.

B9. Yararbaş U, Erinç R, Karapolat I, Kumanlıoğlu K. Comparison of Pinhole/High Resolution Parallel Hole and Early/Late Tc99m-MIBI Images in Parathyroid Imaging. Congress of the European Association of Nuclear Medicine, Napoli, Italy, 2001.

B10. Dirlik A, Erinç R, Burak Z, Karapolat I, Tavus S, Bacakoglu F. Assesment of alveolar epithelial permeability in diabetics using 99mTc DTPA aerosol scintigraphy. Congress of the European Assocation of Nuclear Medicine, Paris, France, 2000.   

      C. Ulusal hakemli dergilerde yayınlanan makaleler :

C1. İnanç Karapolat. Akciğer Kanserinde Tedavi Yanıtını Değerlendirmede FDG PET/BT Görüntüleme. Nucl Med Semin 2018;4:43-51.

C2. Hatipoğlu F, Karapolat I, Ömür Ö, Akgün A, Yanarateş A, Kumanlıoğlu K. Recurrence Incidence in Differentiated Thyroid Cancers and the Importance of Diagnostic Iodine-131 Scintigraphy in Clinical Follow-up. Mol Imaging Radionucl Ther 2016 Jun 5;25(2):85-90. 

C3. Mine Genc, Berhan Genc, Serap Karaarslan, Secil Kurtulmus, Seyhan Yalaz, İnanç Karapolat. Concurrent Endometrial Carcinosarcoma and Thyroid Papillary Carcinoma: PET CT Imaging Findings. Mol Imaging Radionucl Ther 2015; 24: 34-37.

C4. Karapolat I, Kumanlıoğlu K. Enfeksiyöz ve Enflamatuar Hastalıkların Pozitron Emisyon Tomografi/Bilgisayarlı Tomografi ile Görüntülenmesi. Düzce Üniversitesi Tıp Fakültesi Dergisi. 2014 16(2):63-69

C5. Karapolat I, Oncel G, Kumanlıoğlu K. Clinically Occult Pituitary Adenoma Can Appear as a Hypermetabolic Lesion on Whole Body FDG PET Imaging in a Patient with Lymphoma. Mol Imaging Radionucl Ther. 2013 Apr;22(1):18-20.

C6. Karapolat I, Kumanlıoğlu K. Impact of FDG-PET/CT for the Detection of Unknown Primary Tumours in Patients with Cervical Lymph Node Metastases. Mol Imaging Radionucl Ther. 2012 Aug;21(2):63-8.

C7. Cok G, Karapolat I, Turhan K, Göksel T, Cakan A, Nart D, Kumanlıoğlu K. Akciğer Kanserlerinin Tanı ve Evrelemesinde Pozitron Emisyon Tomografisinin Tanısal Değeri. Solunum 2006; Vol: 8 Sayı: 2 Sayfa: 55-59.

C8. Yıldız F, Özyurt Ö, Karapolat I, Oncel G, Kumanlıoğlu K, Oncel D. Erken Evre Akciğer Kanseri Olgularımızın Klinik ve Görüntüleme Bulguları (Radyoloji ve PET). Turk. J. Nuc. Med. 2007, 16.

C9. Kömürcülü N, İnce A, Bakar E, Yılmaz H, Karapolat I, Selçuki D. Huntington Hastalığı: İki Olgu. Ege Tıp Dergisi 45 (2): 139-143, 2006.

C10. Özgür Ö, Özcan Z, Akgün A, Karapolat İ, Özkılıç H. Papillary microcarcinoma of the thyroid gland presenting initially with regional or distant metastasis. Turk. J. Nucl. Med. 2005, Volume 14, No:4.

C11. Özgür Ö, Karapolat İ. Kalsifikasyon odağı saptanmayan metastatik karaciğer lezyonunda Tc99m MDP tutulumu. Turk. J. Nucl. Med. 2002, Volume 11, No:4.

D. Ulusal bilimsel toplantılarda sunulan ve bildiri kitabında basılan bildiriler :

D1. Fidan Sever, Aşkın Gülşen, Ayşe Pelin Girgin, Filiz Hatipoğlu, İnanç Karapolat, Güray Öncel. Bronkoskopik Volüm Azaltıcı Sarmal tedavisi (LVRC) öncesi V/Q Sintigrafi değerlendirmesinin işlemin etkinliğini belirlemedeki rolü. TÜSAD 37. Ulusal Kongresi. İzmir, Türkiye, Ekim 2015

D2. Karapolat I, Sertpoyraz F, Öncel G, Kobak Ş, Kumanlıoğlu K. F-18 FDG PET-BT Romatoid Artrit Hastalarında Hastalık Aktivitesini Göstermede Duyarlı Bir Yöntem midir?. 25. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye, 2013

D3. Çerçi U, Bozdemir E, Karapolat I. Servikal Lenf Bezi Metastazı olan Hastalarda Primer Odak Araştırılmasında FDG PET/BT'nin Etkinliği, 34. Türk Ulusal Kulak Burun Boğaz ve Baş Boyun Cerrahisi Kongres,. Antalya, Türkiye, Ekim 2012

D4. Yalçın M, Karadeniz M, Genç B, Öncel G, Karapolat I, Sever F. Mediastende Ektopik Paratiroid Adenomu ve Ciddi Vitamin D3 Eksikliği Olan Olgu. İstanbul Tıp Fakültesi Geleneksel İç Hastalıkları Günleri, İstanbul, Türkiye, Mart 2012

D5. Yalçın M, Sivrikoz O, Karaarslan S, Karapolat I, Sanal S. Meme ve Paratiroid Kanseri Birlikteliği Olan Bir Olgu. İstanbul Tıp Fakültesi Geleneksel İç Hastalıkları Günleri, İstanbul, Türkiye, Mart 2012

D6. Yalçın M, Karadeniz M, Sanal S, Demir Ö, Karapolat I, Gökduman A,  Buğdaycı H, Arıcan A, Kırcı A. Pankreas Başında Yerleşmiş Tıkanma Sarılığı ve Kan Şekeri Yükselmesiyle Teşhis Edilen Granülositik Sarkom Olgusu. İstanbul Tıp Fakültesi Geleneksel İç Hastalıkları Günleri, İstanbul, Türkiye, Mart 2012

D7. Argon M, Yararbaş U, Karapolat I. PET-BT’de Hatalı Pozitiflik Nedenlerinden Biri: Sarkoidoz, 23. Ulusal Nükleer Tıp Kongresi, İzmir, Türkiye, 2011

D8. Sivrikoz N.O, Karaarslan S, Karapolat I. Primer Tiroid Angiosarkomu: Olgu Sunumu, 21. Ulusal Patoloji Kongresi, İzmir, Türkiye, 2011

D9. Karapolat I, Özyurt Ö, Kumanlıoğlu K, Kuşçu B. Yaygın akciğer tüberkülozlu bir olguda PET/BT bulguları. 21. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye 2009.

D10. Karapolat I, Özyurt Ö, Kumanlıoğlu K, Uyar M. Orbital lenfomalı bir olguda PET/BT ile evreleme ve tedaviye yanıtın değerlendirilmesi. 21. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye 2009.

D11. Özyurt Ö, Karapolat I, Kumanlıoğlu K, Hacıbeyoğlu I, Tunç M. PET çalışmasında Geç Görüntünün Önemi; Serviks Karsinomu Tanılı Olgunun Tedavi Sonrası Değerlendirilmesi. Nükleer Tıp Sempozyumu Pozitron Emisyon Tomografi konferansı, Ankara, Türkiye, Mart 2005

D12. Özyurt Ö, Karapolat I, Kumanlıoğlu K, Hacıbeyoğlu I, Tunç M. Metastaz Taraması Nedeniyle PET Tetkiki Yapılan ve Tesadüfen Primer Tiroid Malignitesi Saptanan Olgu. Nükleer Tıp Sempozyumu Pozitron Emisyon Tomografisi konferansı, Ankara, Türkiye, Mart 2005

D13. Dirlik A, Çok G, Karapolat I, Göksel T, Burak Z. Küçük hücreli akciğer kanserinde kemoterapi yanıtını önceden belirlemede Tc99m MIBI SPECT. 16. Ulusal Nükleer Tıp Kongresi, Samsun, Türkiye 2003.

D14. Karapolat I, Özcan Z, Dirlik A, Ömür Ö, Kumanlıoğlu K, Özkılıç H. Çocukluk çağında papiller tiroid kanserleri. 16. Ulusal Nükleer Tıp Kongresi, Samsun, Türkiye 2003.

D15. Dirlik A, Karapolat I, Göksel T, Özcan Z, Burak Z. Comparison of Tc-99m MIBI uptake ratios in lung cancer using two different regions of interests. 15.Ulusal Nükleer Tıp Kongresi, Kuşadası, Türkiye 2002.

Academic Titles :

Assistant Professor Date: 25.04.2011

Associate Professorship Date: 27.01.2014

Training Period as an Overseas Observer:

1. Cleveland Clinic Department of Molecular and Functional Imaging Observership Program Cleveland/USA - 2005

2. University of Pittsburgh Department of Nuclear Medicine PET/CT Observership Program Pittsburgh/USA – 2007

Certificates of Achievement:

1. Interuniversity Board Foreign Language Exam (ÜDS) - English Health Sciences - 86.250 – 25.03.2007

2. Turkish Board of Nuclear Medicine - November 2009

3. European Board of Nuclear Medicine - May 2010

Publications :

Articles published in international peer-reviewed journals:

A1. Cokmert S, Tanriverdi O, Karapolat I, Demir L, Bayoglu V, Can A, Akyol M, Yılmaz Y, Oktay Tarhan M. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study. JBUON. 2016 Nov-Dec;21(6):1410-1418.

A2. Öztürk H, Karapolat I. 18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer. Oncol Lett. 2016 Jan;11(1):316-322. 

A3. Karapolat I, Karapolat HU, Kirazli Y, Capaci K, Akkoc Y, Kumanlioglu K. Longitudinal study of bone loss in chronic spinal cord injury patients. J Phys Ther Sci. 2015 May;27(5):1429-33.

A4. Ozturk H, Karapolat I, Saklamaz A. Bilateral metachronous adrenal metastases of operated renal cell carcinoma. Urologia. 2015 Apr-Jun;82(2):114-7.

A5. Öztürk H, Karapolat I. Efficacy of 18F-fluorodeoxyglucose-positron emission  tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy. Exp Ther Med. 2015 Mar;9(3):717-724.

A6. Oncel G, Oncel D, Karapolat I, Sever F. The effectiveness of whole body magnetic resonance imaging (diffusion-weighted imaging and fat saturated T2-weighted imaging) in the evaluation of patients with newly diagnosed malignancies in comparison with positron emission tomography-computed tomography. JBR-BTR. 2014 Nov-Dec;97(6):341-5.

A7. Karapolat I, Sertpoyraz F, Oncel G, Kobak S, Yalcin M, Kumanlioglu K. Demonstrating disease activity in patients with rheumatoid arthritis. Is 18F FDG PET a sensitive method? Nuklearmedizin. 2013 Dec 13;52(6):244-9.

A8. Karapolat I, Kalfa M, Keser G, Yalcin M, Inal V, Kumanlioglu K, Parildar T, Aksu K. Comparison of F18 FDG PET/CT findings with current clinical disease status in patients with Takayasu's arteritis. Clin Exp Rheumatol. 2013, 31, 1, Suppl.75:0015-0021.

A9. Sanal SM, Sivrikoz ON, Karapolat I, Karademir S. Complete clinical response in squamous cell carcinoma of the rectum with liver metastases. J Clin Oncol. 2011 Nov 20;29(33):e806-8.

A10. Turker O, Karapolat I, Doğan I. A semihot-semicold but pure adenoma. Thyroid 2008;18:793.

A11. Turker O, Karapolat I. There is immunological benefit of selenium treatment in autoimmune thyroiditidis. Thyroid 2008;18:671-2.

A12. Yulug B, Bakar M, Karapolat I, Guzel O, Schäbitz WR. A case of idiopathic basal ganglia calcification presenting with only acting-out attacks and mild cognitive impairment: PET findings. J. Neuropsychiatry Clin. Neurosci. 2007;19:348-9.

A13. Yulug B, Bakar M, Karapolat I, Guzel O, Schäbitz WR. Topiramate improves glucose  metabolism in choreatic and depressive patient: PET findings. J. Neuropsychiatry Clin. Neurosci. 2007;19:346-7.

A14. Akgun A, Cok G, Karapolat I, Goksel T, Burak Z. Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer. Ann. Nucl. Med. 2006;20:269-75.

A15. Turker O, Kumanlioglu K, Karapolat I, Dogan I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J. Endocrinol. 2006;190:151-6.

B. Papers presented at international scientific meetings and published in the proceedings book

B1. Fidan Yildiz, Inanc Karapolat, Güray Oncel. Role of quantitative perfusion scintigraphy evaluation in determination of the efficiency of the procedure before lung volume reduction coil (LVRC) treatment for severe emphysema. European Respiratory Society International Congress, London, UK, 2016

B2. Karapolat Inanc, Sertpoyraz Filiz, Oncel Guray, Kobak Senol, Kumanlioglu Kamil. Is F-18 FDG PET a sensitive method in demonstrating disease activity in patients with rheumathoid arthritis? Second Balkan Congress of Nuclear Medicine Belgrade, Serbia, 2013.

B3. Yilmaz, E; Akkoclu, A; Gulsen, A; Sever, F; Genc, B; Kalaycioglu, S; Karapolat, I; Onen, A. Comparison of diffusion-weighted magnetic resonance imaging versus F-18 fluorodeoxyglucose positron emission tomography in the assessment of N2 lymph node metastasis due to non-small cell lung cancer. World Conference on Lung Cancer (WCLC), Sydney, Australia, 2013.

B4. Argon, M; Tani, E; Omur, O; Oral, A; Karapolat, I; Yararbas, U. The value of diffuse slow washout rate of Tl-201 in type 2 diabetes mellitus patients with and without perfusion defects in myocardial perfusion scintigraphy. 25th Annual Congress of the European Association of Nuclear Medicine (EANM), Milan, Italy, 2012.

B5. Akgun A, Yuceyar N, Karapolat I, Ozbelen Alper Y, Kocaman A. Is There any Correlation Between Fatigue in Multipl Sclerosis and Cerebral Blood Flow as Detected by Tc-99m HMPAO SPECT?. Annual Congress of the EANM, Istanbul, Turkey 2005.

B6. Akgun A, Cok G, Karapolat I, Goksel T, Burak Z. Tc-99m MIBI SPECT as an indicator of prognosis for patients with small cell lung cancer. Annual Congress of the EANM, Istanbul, Turkey 2005.

B7. Hacibeyoglu I, Ozyurt O, Asıkoglu M, Karapolat I, Tunc M. Biodistribution of F-18 FDG (fluoro-2-deoxyglucose) in rabbits. International Congress of Radiopharmacy and Radiopharmaceutical Chemistry, Istanbul, Turkey 2004. 

B8. Özcan Z, Karapolat I, Dirlik A, Ömür Ö, Kumanlıoğlu K, Özkılıç H. Papillary Thyroid Carcinoma in Childhood and Adolescence. Annual Congress of the EANM, Amsterdam, Holland, 2003.

B9. Yararbaş U, Erinç R, Karapolat I, Kumanlıoğlu K. Comparison of Pinhole/High Resolution Parallel Hole and Early/Late Tc99m-MIBI Images in Parathyroid Imaging. Congress of the European Association of Nuclear Medicine, Napoli, Italy, 2001.

B10. Dirlik A, Erinç R, Burak Z, Karapolat I, Tavus S, Bacakoglu F. Assesment of alveolar epithelial permeability in diabetics using 99mTc DTPA aerosol scintigraphy. Congress of the European Assocation of Nuclear Medicine, Paris, France, 2000.   

C. Articles published in national peer-reviewed journals:

C1. İnanç Karapolat. Akciğer Kanserinde Tedavi Yanıtını Değerlendirmede FDG PET/BT Görüntüleme. Nucl Med Semin 2018;4:43-51.

C2. Hatipoğlu F, Karapolat I, Ömür Ö, Akgün A, Yanarateş A, Kumanlıoğlu K. Recurrence Incidence in Differentiated Thyroid Cancers and the Importance of Diagnostic Iodine-131 Scintigraphy in Clinical Follow-up. Mol Imaging Radionucl Ther 2016 Jun 5;25(2):85-90. 

C3. Mine Genc, Berhan Genc, Serap Karaarslan, Secil Kurtulmus, Seyhan Yalaz, İnanç Karapolat. Concurrent Endometrial Carcinosarcoma and Thyroid Papillary Carcinoma: PET CT Imaging Findings. Mol Imaging Radionucl Ther 2015; 24: 34-37.

C4. Karapolat I, Kumanlıoğlu K. Enfeksiyöz ve Enflamatuar Hastalıkların Pozitron Emisyon Tomografi/Bilgisayarlı Tomografi ile Görüntülenmesi. Düzce Üniversitesi Tıp Fakültesi Dergisi. 2014 16(2):63-69

C5. Karapolat I, Oncel G, Kumanlıoğlu K. Clinically Occult Pituitary Adenoma Can Appear as a Hypermetabolic Lesion on Whole Body FDG PET Imaging in a Patient with Lymphoma. Mol Imaging Radionucl Ther. 2013 Apr;22(1):18-20.

C6. Karapolat I, Kumanlıoğlu K. Impact of FDG-PET/CT for the Detection of Unknown Primary Tumours in Patients with Cervical Lymph Node Metastases. Mol Imaging Radionucl Ther. 2012 Aug;21(2):63-8.

C7. Cok G, Karapolat I, Turhan K, Göksel T, Cakan A, Nart D, Kumanlıoğlu K. Akciğer Kanserlerinin Tanı ve Evrelemesinde Pozitron Emisyon Tomografisinin Tanısal Değeri. Solunum 2006; Vol: 8 Sayı: 2 Sayfa: 55-59.

C8. Yıldız F, Özyurt Ö, Karapolat I, Oncel G, Kumanlıoğlu K, Oncel D. Erken Evre Akciğer Kanseri Olgularımızın Klinik ve Görüntüleme Bulguları (Radyoloji ve PET). Turk. J. Nuc. Med. 2007, 16.

C9. Kömürcülü N, İnce A, Bakar E, Yılmaz H, Karapolat I, Selçuki D. Huntington Hastalığı: İki Olgu. Ege Tıp Dergisi 45 (2): 139-143, 2006.

C10. Özgür Ö, Özcan Z, Akgün A, Karapolat İ, Özkılıç H. Papillary microcarcinoma of the thyroid gland presenting initially with regional or distant metastasis. Turk. J. Nucl. Med. 2005, Volume 14, No:4.

C11. Özgür Ö, Karapolat İ. Kalsifikasyon odağı saptanmayan metastatik karaciğer lezyonunda Tc99m MDP tutulumu. Turk. J. Nucl. Med. 2002, Volume 11, No:4.

D. Papers presented at national scientific meetings and published in the proceedings book:

D1. Fidan Sever, Aşkın Gülşen, Ayşe Pelin Girgin, Filiz Hatipoğlu, İnanç Karapolat, Güray Öncel. Bronkoskopik Volüm Azaltıcı Sarmal tedavisi (LVRC) öncesi V/Q Sintigrafi değerlendirmesinin işlemin etkinliğini belirlemedeki rolü. TÜSAD 37. Ulusal Kongresi. İzmir, Türkiye, Ekim 2015

D2. Karapolat I, Sertpoyraz F, Öncel G, Kobak Ş, Kumanlıoğlu K. F-18 FDG PET-BT Romatoid Artrit Hastalarında Hastalık Aktivitesini Göstermede Duyarlı Bir Yöntem midir?. 25. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye, 2013

D3. Çerçi U, Bozdemir E, Karapolat I. Servikal Lenf Bezi Metastazı olan Hastalarda Primer Odak Araştırılmasında FDG PET/BT'nin Etkinliği, 34. Türk Ulusal Kulak Burun Boğaz ve Baş Boyun Cerrahisi Kongres,. Antalya, Türkiye, Ekim 2012

D4. Yalçın M, Karadeniz M, Genç B, Öncel G, Karapolat I, Sever F. Mediastende Ektopik Paratiroid Adenomu ve Ciddi Vitamin D3 Eksikliği Olan Olgu. İstanbul Tıp Fakültesi Geleneksel İç Hastalıkları Günleri, İstanbul, Türkiye, Mart 2012

D5. Yalçın M, Sivrikoz O, Karaarslan S, Karapolat I, Sanal S. Meme ve Paratiroid Kanseri Birlikteliği Olan Bir Olgu. İstanbul Tıp Fakültesi Geleneksel İç Hastalıkları Günleri, İstanbul, Türkiye, Mart 2012

D6. Yalçın M, Karadeniz M, Sanal S, Demir Ö, Karapolat I, Gökduman A,  Buğdaycı H, Arıcan A, Kırcı A. Pankreas Başında Yerleşmiş Tıkanma Sarılığı ve Kan Şekeri Yükselmesiyle Teşhis Edilen Granülositik Sarkom Olgusu. İstanbul Tıp Fakültesi Geleneksel İç Hastalıkları Günleri, İstanbul, Türkiye, Mart 2012

D7. Argon M, Yararbaş U, Karapolat I. PET-BT’de Hatalı Pozitiflik Nedenlerinden Biri: Sarkoidoz, 23. Ulusal Nükleer Tıp Kongresi, İzmir, Türkiye, 2011

D8. Sivrikoz N.O, Karaarslan S, Karapolat I. Primer Tiroid Angiosarkomu: Olgu Sunumu, 21. Ulusal Patoloji Kongresi, İzmir, Türkiye, 2011

D9. Karapolat I, Özyurt Ö, Kumanlıoğlu K, Kuşçu B. Yaygın akciğer tüberkülozlu bir olguda PET/BT bulguları. 21. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye 2009.

D10. Karapolat I, Özyurt Ö, Kumanlıoğlu K, Uyar M. Orbital lenfomalı bir olguda PET/BT ile evreleme ve tedaviye yanıtın değerlendirilmesi. 21. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye 2009.

D11. Özyurt Ö, Karapolat I, Kumanlıoğlu K, Hacıbeyoğlu I, Tunç M. PET çalışmasında Geç Görüntünün Önemi; Serviks Karsinomu Tanılı Olgunun Tedavi Sonrası Değerlendirilmesi. Nükleer Tıp Sempozyumu Pozitron Emisyon Tomografi konferansı, Ankara, Türkiye, Mart 2005

D12. Özyurt Ö, Karapolat I, Kumanlıoğlu K, Hacıbeyoğlu I, Tunç M. Metastaz Taraması Nedeniyle PET Tetkiki Yapılan ve Tesadüfen Primer Tiroid Malignitesi Saptanan Olgu. Nükleer Tıp Sempozyumu Pozitron Emisyon Tomografisi konferansı, Ankara, Türkiye, Mart 2005

D13. Dirlik A, Çok G, Karapolat I, Göksel T, Burak Z. Küçük hücreli akciğer kanserinde kemoterapi yanıtını önceden belirlemede Tc99m MIBI SPECT. 16. Ulusal Nükleer Tıp Kongresi, Samsun, Türkiye 2003.

D14. Karapolat I, Özcan Z, Dirlik A, Ömür Ö, Kumanlıoğlu K, Özkılıç H. Çocukluk çağında papiller tiroid kanserleri. 16. Ulusal Nükleer Tıp Kongresi, Samsun, Türkiye 2003.

D15. Dirlik A, Karapolat I, Göksel T, Özcan Z, Burak Z. Comparison of Tc-99m MIBI uptake ratios in lung cancer using two different regions of interests. 15.Ulusal Nükleer Tıp Kongresi, Kuşadası, Türkiye 2002.

Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer

By

Öztürk, H (Ozturk, Hakan) [1] , [3] ; Karapolat, I (Karapolat, Inanc) [2]

 (provided by Clarivate) 

Source

WORLD JOURNAL OF CLINICAL CASES

Volume

11

Issue

36

DOI

10.12998/wjcc.v11.i36.8447

Published

DEC 26 2023

Indexed

2024-02-09

Document Type

Article

Jump to

Abstract

BACKGROUNDThe purpose of the present study was to examine retrospectively the contribution of (18)Fluorodeoxyglucose positron emission tomography computed tomography ((18)FDG-PET/CT) to the evaluation of response to first-line gemcitabine plus cisplatin-based chemotherapy in patients with metastatic bladder cancer. AIMTo evaluate the response to Gemcitabine plus Cisplatin -based chemotherapy using (18)FDG-PET/CT imaging in patients with metastatic bladder cancer. METHODSBetween July 2007 and April 2019, 79 patients underwent (18)FDG-PET/CT imaging with the diagnosis of Metastatic Bladder Carcinoma (M-BCa). A total of 42 patients (38 male, 4 female) were included in the study, and all had been administered Gemcitabine plus Cisplatin-based chemotherapy. After completion of the therapy, the patients underwent a repeat (18)FDG-PET/CT scan and the results were compared with the PET/CT findings before chemotherapy according to European Organisation for the Research and treatment of cancer criteria. Mean age was 66.1 years and standard deviation was 10.7 years (range: 41-84 years). RESULTSOf the patients, seven (16.6%) were in complete remission, 17 (40.5%) were in partial remission, six (14.3%) had a stable disease, and 12 (28.6%) had a progressive disease. The overall response rate was 57.1 percent. CONCLUSION(18)FDG-PET/CT can be considered as a successful imaging tool in evaluating response to first-line chemotherapy for metastatic bladder cancer. Anatomical and functional data obtained from PET/CT scans may be useful in the planning of secondline and thirdline chemotherapy.

Keywords

Author Keywords

Metastatic bladder cancer Response to chemotheraphy Positron emission tomography computed

Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses

By

Turker, O (Turker, Omer) ; Kumanlioglu, K (Kumanlioglu, Kamil) ; Karapolat, I (Karapolat, Inanc) ; Dogan, I (Dogan, Ismail)

 (provided by Clarivate) 

Source

JOURNAL OF ENDOCRINOLOGY

Volume

190

Issue

1

Page

151-156

DOI

10.1677/joe.1.06661

Published

JUL 2006

Indexed

2006-07-01

Document Type

Article

Abstract

The aim of this study is to investigate the long-term (9 months) effects of variable doses (200/100 mu g/day) of L-selenomethionine on autoimmune thyroiditis (AIT) and the parameters affecting the success rate of this therapy. The present study was designed in three steps: (1) 88 female patients with AIT (mean age = 40(.)1 +/- 13(.)3 years) were randomized into two groups according to their initial serum TSH, thyroid peroxidase antibody (TPOAb) concentrations, and age. All the patients were receiving L-thyroxine to keep serum TSH <= 2 mIU/1. Group S2 (n = 48, mean TPOAb = 803(.)9 +/- 483(.)8 IU/ml) received 200 mu g L-selenomethionine per day, orally for 3 months, and group C (n=40, mean TPOAb=770(.)3 +/- 406(.)2 IU/ml) received placebo. (2) 40 volunteers of group S2 were randomized into two age- and TPOAb-matched groups. Group S22 (n = 20) went on taking L-selenomethionine 200 mu g/day, while others (group S21) lowered the dose to 100 mu g/day. (3) 12 patients of group S22 (group S222) went on taking L-Selenomethionine 200 mu g/day, while 12 patients of group S21 (S212) increased the dose to 200 mu g/day. Serum titers of TPOAb decreased significantly in group S2 (26(.)2%, P < 0(.)001), group S22 (23(.)7%, P < 0(.)01) and group S212 (30(.)3%, P < 0(.)01). There were no significant changes in group C and group S222 (P > 0(.)05). TPOAb titers increased significantly in group S21 (38(.)1 %, P < 0(.)01). A significant decrease in thyroglobulin antibody titers was only noted in group S2 (5(.)2%, P < 0(.)01). L-Selenornethionine substitution suppresses serum concentrations of TPOAb in patients with AIT, but suppression requires doses higher than 100 mu g/day which is sufficient to maximize glutathione peroxidase activities. The suppression rate decreases with time.

Keywords

Keywords Plus

IODINE-DEFICIENTINT RINSIC ASTHMA WHOLE-BLOOD SUPPLEMENTATION DISEASES

Efficacy of ¹⁸F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy

By

Öztürk, H (Ozturk, Hakan) [1] ; Karapolat, I (Karapolat, Inanc) [2]

 (provided by Clarivate) 

Source

EXPERIMENTAL AND THERAPEUTIC MEDICINE

Volume

9

Issue

3

Page

717-724

DOI

10.3892/etm.2015.2187

Published

MAR 2015

Indexed

2015-04-08

Document Type

Article

Abstract

The aim of the present study was to retrospectively evaluate the contribution and effectiveness of F-18-fluorodeoxyglucose-positron emission tomography/computed tomography (F-18-FDG-PET/CT) scans in the restaging of patients following radical cystectomy due to muscle-invasive bladder carcinoma (MIBC). A total of 51 patients (45 males and six females) who underwera radical cystectomy due to invasive bladder cancer, and had an 18F-FDG-PET/CT scan for restaging between July 2007 and April 2013, were included in the present study. The mean age Was 62.3 +/- 9.79 years (range, 40-82 years). Patients underwent a six-hour fast prior to scanning, and whole-body PET scanning from the skull base to the upper thighs was performed similar to 1 h after the intravenous injection of 555 MBq F-18-FDG. Whole-body CT scanning was performed in a cranio-caudal direction. F-18-FDG-PET images were reconstructed using CT data for attenuation correction. Histopathology or clinical follow-up was used to confirm any suspicious recurrent or metastatic lesions. The results for sensitivity, specificity, positive predictive value (PPV), negative predictive value and accuracy of F-18-FDG-PET/CT were 92, 83, 94, 77 and 90%, respectively. In conclusion, F-18-FDG-PET/CT efficiently detects local recurrence and distant metastases with high sensitivity and PPV in the restaging of patients who underwent radical cystectomy due to invasive bladder cancer. This procedure could play an important role in rendering decisions regarding radiotherapy or chemotherapy and post-operative follow-up, and could influence the entire decision-making process.

Keywords

Author Keywords

bladder cancer muscle-invasive bladder cancer cystectomy positron emission tomography

F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer

By

Öztürk, H (Ozturk, Hakan) [1] ; Karapolat, I (Karapolat, Inanc) [2]

 (provided by Clarivate) 

Source

ONCOLOGY LETTERS

Volume

11

Issue

1

Page

316-322

Part

A

DOI

10.3892/ol.2015.3903

Published

JAN 2016

Indexed

2016-01-27

Document Type

Article

Abstract

The present study aimed to retrospectively review the contribution of F-18-fluorodeoxygluose-positron emission tomography/computed tomography (F-18-FDG PET/CT) in the assessment of biochemical recurrence in patients with a diagnosis of local-stage prostate cancer (PCa) who underwent radical prostatectomy (RP) or received external beam radiation therapy (EBRT). A total of 28 patients who underwent RP or received EBRT for PCa between July 2007 and April 2013, and who underwent F-18-FDG PET/CT scanning for re-staging due to biochemical recurrence were included in the present study. The mean age of the patients was 65.07 years and the standard deviation was 7.51 years (range, 51-82 years). Of the 28 patients, 23 (82.1%) underwent RP and 5 (17.9%) received definitive EBRT. Prior to scanning, all patients were required to fast for 6 h, and similar to 1 h after the intravenous injection of 555 MBq F-18-FDG, whole-body PET scans were performed from the skull base to the upper thighs. Whole-body CT scans were performed in the craniocaudal direction. F-18-FDG PET images were reconstructed using CT data for attenuation correction. Histopathology examination or clinical follow-up was used to confirm any suspicious recurrent or metastatic lesions. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of F-18-FDG PET/CT were 61.6, 75.0, 61.6, 75.0 and 71.4%, respectively. F-18-FDG PET/CT can detect local and distant metastases with a high accuracy in the assessment of biochemical recurrence, thus detecting occult metastases and allowing the re-staging of PCa in the patients receiving definitive treatment. It is considered that F-18-FDG PET/CT may be useful in re-assessing the patients with PCa receiving definitive treatment.

Keywords

Author Keywords

prostate cancer positron emission tomography/computed tomography restaging occult

Longitudinal study of bone loss in chronic spinal cord injury patients

By

Karapolat, I (Karapolat, Inanc) [1] ; Karapolat, HU (Karapolat, Hale Uzumcugil) [2] ; Kirazli, Y (Kirazli, Yesim) [2] ; Capaci, K (Capaci, Kazim) [2] ; Akkoc, Y (Akkoc, Yesim) [2] ; Kumanlioglu, K (Kumanlioglu, Kamil) [3]

 (provided by Clarivate) 

Source

JOURNAL OF PHYSICAL THERAPY SCIENCE

Volume

27

Issue

5

Page

1429-1433

DOI

10.1589/jpts.27.1429

Published

MAY 2015

Indexed

2015-07-05

Document Type

Article

Abstract

[Purpose] This prospective longitudinal study evaluated the changes in bone metabolism markers and bone mineral density of spinal cord injury patients over 3 years. We also assessed the relationships among the bone mineral density, bone metabolism, and clinical data of spinal cord injury patients. [Subjects and Methods] We assessed the clinical data (i.e., immobilization due to surgery, neurological status, neurological level, and extent of lesion) in 20 spinal cord injury patients. Bone mineral density, and hormonal and biochemical markers of the patients were measured at 0, 6, 12, and 36 months. [Results] Femoral neck T score decreased significantly at 36 months (p < 0.05). Among the hormonal markers, parathyroid hormone and vitamin D were significantly elevated, while bone turnover markers (i.e., deoxypyridinoline and osteocalcin) were significantly decreased at 12 and 36 months (p < 0.05). [Conclusion] Bone mineral density of the femoral neck decreases significantly during the long-term follow-up of patients with spinal cord injury due to osteoporosis. This could be due to changes in hormonal and bone turnover markers.

Keywords

Author Keywords

Bone loss Spinal cord injury Bone mineral density

The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study

By

Cokmert, S (Cokmert, Suna) [1] ; Tanriverdi, O (Tanriverdi, Ozgur) [2] ; Karapolat, I (Karapolat, Inanc) [3] ; Demir, L (Demir, Lutfiye) [1] ; Bayoglu, V (Bayoglu, Vedat) [1] ; Can, A (Can, Alper) [1] ; Akyol, M (Akyol, Murat) [1] ; Yilmaz, Y (Yilmaz, Yasar) [1] ; Tarhan, MO (Tarhan, Mustafa Oktay) [1]

 (provided by Clarivate) 

Source

JOURNAL OF BUON

Volume

21

Issue

6

Page

1410-1418

Published

NOV-DEC 2016

Indexed

2017-03-01

Document Type

Review

Abstract

Purpose: The purpose of this study was to analyse the association between the 18F-2-deoxy-2-fluorodeoxyglucose maximum standardized uptake value (SUVmax) of metastatic sites and molecular subtypes and survival in metastatic breast cancer (MBC) patients.

Methods: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) was performed in 176 MBC patients before any therapeutic intervention. The FDG uptakes of metastatic sites were evaluated using the SUVmax. Histopathological prognostic parameters, such as the tumor size, grade, lymph node involvement, lymphovascular invasion, estrogen (ER), progesterone receptors (PR), HER2 status and Ki67 were determined from the primary breast tumor tissue. The SUVmax of the metastatic sites was assessed in relation to the molecular subtypes and survival in univariate and multivariate analyses. Cox regression analysis was used to evaluate the associations between SUVmax measurements and overall survival (OS).

Results: The mean SUVmax of 176 tumors was 8.0. Among the subtypes 49 (28.8%) were luminal A, 51 (28.9%) luminal B, 35 (19.8%) HER2-overexpressing, and 41 (23.2%) triple-negative, and the corresponding means of SUVmax were 5.6, 7.4, 11.4, 11.0, respectively. A cut-off value of :5.8.4 yielded 80% sensitivity and 57.1% specificity with an area under the receiver operating characteristics curve (AUC) of 0.731 for predicting that a tumor was of the luminal A subtype. A cut-off value of SUVmax >= 10.05 yielded 62.9% sensitivity and 67.4% specificity with an AUC of 0.648 for predicting a HER2 overexpressing subtype. A cut-off value of SUVmax >= 9.25 yielded 61% sensitivity and 64.4% specificity with an AUC of 0.660 for predicting a triple-negative subtype. The SUVmax could not effectively differentiate patients with luminal B subtype. Cox regression analysis showed that in patients with MBC, a SUVmax <= 7.55 acted as an independent negative prognostic factor for OS (hazard ratio/HR = 1.552).

Conclusion: The SUVmax of metastatic sites on pretreatment 18F-FDG PET/CT may be an independent prognostic factor for the diagnosis of molecular phenotypes and survival in MBC patients.

Keywords

Author Keywords

breast cancer molecular subtype PET/CT survival

Impact of FDG-PET/CT for the Detection of Unknown Primary Tumours in Patients with Cervical Lymph Node Metastases

By

Karapolat, I (Karapolat, Inanc) [1] ; Kumanlioglu, K (Kumanlioglu, Kamil) [2]

 (provided by Clarivate) 

Source

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY

Volume

21

Issue

2

Page

63-68

DOI

10.4274/Mirt.344

Published

AUG 2012

Indexed

2012-08-01

Document Type

Article

Abstract

Objective: Because the detection of the primary tumour is of importance to optimize the patient's management and allows a targeted therapy, the performance of hybrid positron emission tomography-computed tomography (PET/CT) using fluorodeoxyglucose (FDG) in the detection of primary tumors and unrecognized metastases with cervical lymph node metastases were evaluated in a retrospective study.

Material and Methods: Twenty patients with cervical lymph node metastases of unknown primary tumors underwent staging with FDG-PET/CT. All underwent head and neck examinations, computed tomography (CT), and/or magnetic resonance imaging (MRI), panendoscopies, and biopsies of head and neck mucosal sites. The diagnostic accuracy of FDG-PET/CT in detecting primary tumors was compared with that of histopathology and clinical follow-up. The ability of FDG-PET/CT to detect distant metastases was also tested.

Results: PET/CT was positive with an increased FDG uptake suggesting the potential primary site in 45% of patients (9/20). PET/CT findings were true positive in 7, true negative in 10, false positive in 2, and false negative in 1 patients, resulting in a sensitivity of 87%, a specificity of 83%, an accuracy of 85%, a positive predictive value of 77% and a negative predictive value of 90%. Also, PET/CT showed distant metastases in seven patients.

Conclusion: FDG-PET/CT can be successfully used for the identification of the primary site and distant metastases in patients with cervical lymph node metastases from an unknown primary cancer.

Keywords

Author Keywords

Neoplasm sunknown primary lymphatic metastasis neoplasm metastasis fluorodeoxyglucose

Recurrence Incidence in Differentiated Thyroid Cancers and the Importance of Diagnostic Iodine-131 Scintigraphy in Clinical Follow-up

By

Hatipoglu, F (Hatipoglu, Filiz) [1] ; Karapolat, I (Karapolat, Inanc) [1] ; Ömür, Ö (Omur, Ozgur) [2] ; Akgün, A (Akgun, Aysegul) [2] ; Yanarates, A (Yanarates, Ahmet) [3] ; Kumanlioglu, K (Kumanlioglu, Kamil) [2]

 (provided by Clarivate) 

Source

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY

Volume

25

Issue

2

Page

85-90

DOI

10.4274/mirt.35220

Published

JUN 2016

Indexed

2016-06-29

Document Type

Article

Abstract

Objective: Differentiated thyroid cancers (DTC) are tumors with good prognosis. However, local recurrence or distant metastasis can be observed. In our study, we aimed to investigate the incidence of recurrence and the importance of diagnostic iodine-131 whole body scan (WBS) in clinical follow-up in patients with DTC.

Methods: The clinical data of 217 patients with DTC who were followed-up more than 3 years were reviewed retrospectively. The incidence of recurrence was investigated in a group of patients who had radioactive iodine (RAI) treatment and showed no sign of residual thyroid tissue or metastasis with diagnostic WBS that was performed at 6-12 months after therapy and had a thyroglobulin (Tg) level lower than 2 ng/dl.

Results: At the time of diagnosis, ten cases had thyroid capsule invasion, 25 cases had extra-thyroid soft tissue invasion, 11 patients showed lymph node metastasis and four patients had distant organ metastasis. One hundred forty-five patients had RAI treatment at ablation dose (75-100 mCi), whereas 35 patients had RAI treatment at metastasis dose (150-200 mCi). Thirty-seven patients with papillary microcarcinoma did not receive RAI treatment. In 12 (%7.5) of the 160 patients who were considered as "successful ablation", a recurrence was identified. Recurrence was detected by diagnostic WBS in all cases and stimulated Tg level was <2 ng/dL with the exception of the two cases who had distant metastasis.

Conclusion: Identification of pathological findings with WBS in patients who developed local recurrence in the absence of elevated Tg highlights the importance of diagnostic WBS in clinical follow-up.

Keywords

Author Keywords

Differentiated thyroid cancer recurrenceiodine-131 scintigraphy

Concurrent Endometrial Carcinosarcoma and Thyroid Papillary Carcinoma: PET CT Imaging Findings

By

Genc, M (Genc, Mine) [1] ; Genc, B (Genc, Berhan) [2] ; Karaarslan, S (Karaarslan, Serap) [3] ; Kurtulmus, S (Kurtulmus, Secil) [4] ; Yalaz, S (Yalaz, Seyhan) [5] ; Karapolat, I (Karapolat, Inanc) [6]

 (provided by Clarivate) 

Source

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY

Volume

24

Page

34-37

Supplement

1

Special Issue

SI

DOI

10.4274/mirt.96268

Published

JUN 2015

Indexed

2015-06-01

Document Type

Article

Abstract

The aim of this study is to report a patient who was diagnosed with a concurrent primary tumor by 18-fluoro-2-deoxy-glucose positron emission tomography (FDG PET) imaging performed for staging of an endometrial cancer. FDG uptake was detected in the uterus, where the primary cancer was located, and in the left lobe of the thyroid gland. The biopsy sample from the hypermetabolic nodular lesion in thyroid gland revealed intermediate cytology according to Bethesda Classification. The patient underwent hysterectomy and thyroidectomy. An endometrial carcinoma in the uterus and a multicentric thyroid papillary carcinoma in the thyroid gland were diagnosed.

Keywords

Author Keywords

Carcinoma of endometrium positron-emission tomography thyroid cancer

Bilateral metachronous adrenal metastases of operated renal cell carcinoma

By

Ozturk, H (Ozturk, Hakan) [1] ; Karapolat, I (Karapolat, Inanc) [2] ; Saklamaz, A (Saklamaz, Ali) [3]

 (provided by Clarivate) 

Source

UROLOGIA JOURNAL

Volume

82

Issue

2

Page

114-117

DOI

10.5301/uro.5000094

Published

APR-JUN 2015

Indexed

2015-04-01

Document Type

Article

Abstract

Background: The adrenal glands are among the target metastatic organs due to the potential of systemic metastasis from renal cell carcinoma (RCC). The number of cases with bilateral metachronous metastases from RCC is about twenty.

Patients and Methods: A sixty-one-year-old man presented for routine checks due to an operated left renal tumor (clear cell carcinoma, PT2N0M0, Fuhrman grade III). The patient underwent (18)FDG-PET/CT in order to re-stage the disease upon observation of bilateral adrenal masses on ultrasound and CT. A bilateral metachronous metastasis was found, whose SUVmax was 6.7 x 50 x 38 x 20 cm on the left adrenal gland, and another metastasis whose SUVmax was 5.5 40 x 29 x 20 on the right adrenal gland.

Results: The patient underwent a CT-guided biopsy and diagnosis of adrenal metastasis was made by pathological and immunohistochemical examination. The laparoscopic treatment was performed.

Conclusions: There is no standard approach for the treatment of these patients in the literature. But metastasectomy is the most realistic part of the treatment. Making definitive diagnosis with biopsy, following hormonal examination and treatment with minimally invasive adrenal sparing surgical procedure containing frozen-section are strongly recommended. Cancer specific survival significantly increases with metastasectomy.

Keywords

Author Keywords

Renal cell carcinoma Adrenal metastasis Metachronous metastasis Diagnosis

Clinically Occult Pituitary Adenoma Can Appear as a Hypermetabolic Lesion on Whole Body FDG PET Imaging in a Patient with Lymphoma

By

Karapolat, I (Karapolat, Inanc) [1] ; Öncel, G (Oncel, Guray) [2] ; Kumanlioglu, K (Kumanlioglu, Kamil) [3]

 (provided by Clarivate) 

Source

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY

Volume

22

Issue

1

Page

18-20

DOI

10.4274/Mirt.258

Published

APR 2013

Indexed

2013-04-01

Document Type

Article

Abstract

We report a case with Non-Hodgkin Lymphoma with a focus of intense hypermetabolism in the sellar region in the primary staging and posttreatment whole body F-18 FDG PET. Further evaluation with magnetic resonance imaging after posttreatment FDG PET revealed a pituitary adenoma. Endocrinologic workup was normal consistent with nonfunctioning pituitary adenoma and endocrinologists decided to follow up the patient by yearly magnetic resonance imaging. This case demonstrates a nonfunctioning pituitary adenoma by whole body FDG PET and emphasizes the importance of pursuing incidental findings detected in the sella on PET imaging.

Keywords

Author Keywords

Fluorodeoxyglucose F18pituitary adenoma positron-emission tomography

Diagnostic Value of Positron Emission Tomography in Stagins of lung cancers

By

Çok, G (Cok, Gursel) [1] ; Karapolat, I (Karapolat, Inanc) [2] ; Turhan, K (Turhan, Kutsal) [3] ; Göksel, T (Goksel, Tuncay) [1] ; Çakan, A (Cakan, Alpaslan) ; Nart, D (Nart, Deniz) [4] ; Kumanlioglu, K (Kumanlioglu, Kamil) [5]

 (provided by Clarivate) 

Source

EURASIAN JOURNAL OF PULMONOLOGY

Volume

8

Issue

2

Page

55-59

Published

APR 2006

Indexed

2006-04-01

Document Type

Article

Abstract

Noninvasive diagnostic methods have an important role in the diagnosis and staging of lung cancers. In recent years, positron emission tomography (PET) was introduced for use in the differentiation of malignant and benign lesions, and also in staging cancers.

Objective: A retrospective study was designed with the aim of examining the role of PET in the diagnosis and staging of lung cancers.

Materials and Methods: A total of 52 patients including 41 males and 11 females who were assessed with an initial diagnosis of lung cancer between April 2003 and September 2004 were analyzed.

Findings: The mean age was 59.5 (+/- 12.4) years. Forty two (88%) of the patients were found to smoke. Forty three of the patients had been diagnosed as having non-small cell lung cancer, 7 were found to have benign pathology, and 2 had been diagnosed as having small cell lung cancer. In PET analysis, involvements above the value of 2.5 SVU were accepted as being pathologic. Overall assessment of the lesions which were detected after PET revealed a sensitivity and specificity of 95.4% and 87.5%, respectively. In addition, the possitive predictive value was found as 97.6 whereas the negative predictive value was 77.7%.

Conclusion: In selected cases, PET is a useful method fort he diagnosis and staging of lung cancer.

Keywords

Author Keywords

diagnosislung cancer PET staging

Bilimsel ve Mesleki Kuruluşlara Üyelikler :

1. Türk Tabipleri Birliği İzmir Tabip Odası
2. Türkiye Nükleer Tıp Derneği
3. Avrupa Nükleer Tıp Derneği